MEF2C-dysregulated pediatric T-cell acute lymphoblastic leukemia is associated with CDKN1B deletions and a poor response to glucocorticoid therapy

References

• Belver L, Ferrando A. The genetics and mechanisms of T cell acute lymphoblastic leukaemia. Nat Rev Cancer. 2016;16:494–507.
   PubMed Web of Science ®Google Scholar
• Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354:166–178.
   PubMed Web of Science ®Google Scholar
• Moricke A, Reiter A, Zimmermann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood. 2008;111:4477–4489.
   PubMed Web of Science ®Google Scholar
• Graux C, Cools J, Michaux L, et al. Cytogenetics and molecular genetics of T-cell acute lymphoblastic leukemia: from thymocyte to lymphoblast. Leukemia. 2006;20:1496–1510.
   PubMed Web of Science ®Google Scholar
• Van Vlierberghe P, Pieters R, Beverloo HB, et al. Molecular-genetic insights in paediatric T-cell acute lymphoblastic leukaemia. Br J Haematol. 2008;143:153–168.
   PubMed Web of Science ®Google Scholar
• Tzoneva G, Ferrando AA. Recent advances on NOTCH signaling in T-ALL. Curr Top Microbiol Immunol. 2012;360:163–182.
   PubMed Web of Science ®Google Scholar
• Durinck K, Goossens S, Peirs S, et al. Novel biological insights in T-cell acute lymphoblastic leukemia. Exp Hematol. 2015;43:625–639.
   PubMed Web of Science ®Google Scholar
• Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009;9:153–166.
   PubMed Web of Science ®Google Scholar
• Mullighan CG, Goorha S, Radtke I, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 2007;446:758–764.
   PubMed Web of Science ®Google Scholar
• Remke M, Pfister S, Kox C, et al. High-resolution genomic profiling of childhood T-ALL reveals frequent copy-number alterations affecting the TGF-beta and PI3K-AKT pathways and deletions at 6q15-16.1 as a genomic marker for unfavorable early treatment response. Blood. 2009;114:1053–1062.
   PubMed Web of Science ®Google Scholar
• Liu Y, Easton J, Shao Y, et al. The genomic landscape of childhood T-lineage acute lymphoblastic leukemia. Blood. 2015;126:691.
   Web of Science ®Google Scholar
• Ferrando AA, Neuberg DS, Staunton J, et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell. 2002;1:75–87.
   PubMed Web of Science ®Google Scholar
• Soulier J, Clappier E, Cayuela JM, et al. HOXA genes are included in genetic and biologic networks defining human acute T-cell leukemia (T-ALL). Blood. 2005;106:274–286.
   PubMed Web of Science ®Google Scholar
• Van Vlierberghe P, van Grotel M, Tchinda J, et al. The recurrent SET-NUP214 fusion as a new HOXA activation mechanism in pediatric T-cell acute lymphoblastic leukemia. Blood. 2008;111:4668–4680.
   PubMed Web of Science ®Google Scholar
• Homminga I, Pieters R, Langerak AW, et al. Integrated transcript and genome analyses reveal NKX2-1 and MEF2C as potential oncogenes in T cell acute lymphoblastic leukemia. Cancer Cell. 2011;19:484–497.
   PubMed Web of Science ®Google Scholar
• Homminga I, Pieters R, Meijerink JP. NKL homeobox genes in leukemia. Leukemia. 2012;26:572–581.
   PubMed Web of Science ®Google Scholar
• Zuurbier L, Gutierrez A, Mullighan CG, et al. Immature MEF2C-dysregulated T-cell leukemia patients have an early T-cell precursor acute lymphoblastic leukemia gene signature and typically have non-rearranged T-cell receptors. Haematologica. 2014;99:94–102.
   PubMed Web of Science ®Google Scholar
• Nagel S, Meyer C, Quentmeier H, et al. MEF2C is activated by multiple mechanisms in a subset of T-acute lymphoblastic leukemia cell lines. Leukemia. 2008;22:600–607.
   PubMed Web of Science ®Google Scholar
• Nagel S, Kaufmann M, Drexler HG, et al. The cardiac homeobox gene NKX2-5 is deregulated by juxtaposition with BCL11B in pediatric T-ALL cell lines via a novel t(5;14)(q35.1;q32.2). Cancer Res. 2003;63:5329–5334.
   PubMed Web of Science ®Google Scholar
• Chen W, Erdogan F, Ropers HH, et al. CGHPRO – a comprehensive data analysis tool for array CGH. BMC Bioinformatics. 2005;6:85.
   PubMed Web of Science ®Google Scholar
• Erdogan F, Chen W, Kirchhoff M, et al. Impact of low copy repeats on the generation of balanced and unbalanced chromosomal aberrations in mental retardation. Cytogenet Genome Res. 2006;115:247–253.
   PubMed Web of Science ®Google Scholar
• Strehl S, Nebral K, Konig M, et al. ETV6-NCOA2: a novel fusion gene in acute leukemia associated with coexpression of T-lymphoid and myeloid markers and frequent NOTCH1 mutations. Clin Cancer Res. 2008;14:977–983.
   PubMed Web of Science ®Google Scholar
• Shochat C, Tal N, Bandapalli OR, et al. Gain-of-function mutations in interleukin-7 receptor-α (IL7R) in childhood acute lymphoblastic leukemias. J Exp Med. 2011;208:901–908.
   PubMed Web of Science ®Google Scholar
• Colomer-Lahiguera S, Strehl S. Complexity of NOTCH1 juxtamembrane insertion mutations in T-cell acute lymphoblastic leukemia. Leuk Lymphoma. 2016;57:1219–1222.
   PubMed Web of Science ®Google Scholar
• Bene MC, Castoldi G, Knapp W, et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia. 1995;9:1783–1786.
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402–408.
   PubMed Web of Science ®Google Scholar
• Bustin SA, Benes V, Garson JA, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 2009;55:611–622.
   PubMed Web of Science ®Google Scholar
• Budczies J, Klauschen F, Sinn BV, et al. Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PLoS One. 2012;7:e51862.
   PubMed Web of Science ®Google Scholar
• Van Vlierberghe P, Ferrando A. The molecular basis of T cell acute lymphoblastic leukemia. J Clin Invest. 2012;122:3398–3406.
   PubMed Web of Science ®Google Scholar
• Van Vlierberghe P, van Grotel M, Beverloo HB, et al. The cryptic chromosomal deletion del(11)(p12p13) as a new activation mechanism of LMO2 in pediatric T-cell acute lymphoblastic leukemia. Blood. 2006;108:3520–3529.
   PubMed Web of Science ®Google Scholar
• Dik WA, Brahim W, Braun C, et al. CALM-AF10+ T-ALL expression profiles are characterized by overexpression of HOXA and BMI1 oncogenes. Leukemia. 2005;19:1948–1957.
   PubMed Web of Science ®Google Scholar
• Van Vlierberghe P, Ambesi-Impiombato A, Perez-Garcia A, et al. ETV6 mutations in early immature human T cell leukemias. J Exp Med. 2011;208:2571–2579.
   PubMed Web of Science ®Google Scholar
• Shima-Rich EA, Harden AM, McKeithan TW, et al. Molecular analysis of the t(8;14)(q24;q11) chromosomal breakpoint junctions in the T-cell leukemia line MOLT-16. Genes Chromosomes Cancer. 1997;20:363–371.
   PubMed Web of Science ®Google Scholar
• La Starza R, Borga C, Barba G, et al. Genetic profile of T-cell acute lymphoblastic leukemias with MYC translocations. Blood. 2014;124:3577–3582.
   PubMed Web of Science ®Google Scholar
• Coustan-Smith E, Mullighan CG, Onciu M, et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol. 2009;10:147–156.
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–2405.
   PubMed Web of Science ®Google Scholar
• Conter V, Valsecchi MG, Buldini B, et al. Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: a retrospective analysis. Lancet Haematol. 2016;3:e80–e86.
   PubMed Web of Science ®Google Scholar
• Attarbaschi A, Pisecker M, Inthal A, et al. Prognostic relevance of TLX3 (HOX11L2) expression in childhood T-cell acute lymphoblastic leukaemia treated with Berlin-Frankfurt-Münster (BFM) protocols containing early and late re-intensification elements. Br J Haematol. 2010;148:293–300.
   PubMed Web of Science ®Google Scholar
• Peirs S, Matthijssens F, Goossens S, et al. ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. Blood. 2014;124:3738–3747.
   PubMed Web of Science ®Google Scholar
• Kawashima-Goto S, Imamura T, Tomoyasu C, et al. BCL2 inhibitor (ABT-737): a restorer of prednisolone sensitivity in early T-cell precursor-acute lymphoblastic leukemia with high MEF2C expression? PLoS One. 2015;10:e0132926.
   PubMed Web of Science ®Google Scholar
• Zhang J, Ding L, Holmfeldt L, et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature. 2012;481:157–163.
   PubMed Web of Science ®Google Scholar
• Haydu JE, Ferrando AA. Early T-cell precursor acute lymphoblastic leukaemia. Curr Opin Hematol. 2013;20:369–373.
   PubMed Web of Science ®Google Scholar
• Patrick K, Wade R, Goulden N, et al. Outcome for children and young people with early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003. Br J Haematol. 2014;166:421–424.
   PubMed Web of Science ®Google Scholar
• Hetet G, Dastot H, Baens M, et al. Recurrent molecular deletion of the 12p13 region, centromeric to ETV6/TEL, in T-cell prolymphocytic leukemia. Hematol J. 2000;1:42–47.
   PubMedGoogle Scholar
• Le Toriellec E, Despouy G, Pierron G, et al. Haploinsufficiency of CDKN1B contributes to leukemogenesis in T-cell prolymphocytic leukemia. Blood. 2008;111:2321–2328.
   PubMed Web of Science ®Google Scholar
• Moricke A, Zimmermann M, Reiter A, et al. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia. 2010;24:265–284.
   PubMed Web of Science ®Google Scholar
• Lauten M, Moricke A, Beier R, et al. Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemia. Haematologica. 2012;97:1048–1056.
   PubMed Web of Science ®Google Scholar
• Peirs S, Frismantas V, Matthijssens F, et al. Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia. Leukemia. 2017 [Feb 3];[1?11]. DOI: 10.1038/leu.2017.10
   PubMedGoogle Scholar